Last reviewed · How we verify
clofarabine, cytarabine, idarubicin
clofarabine, cytarabine, idarubicin is a Small molecule drug developed by Hannover Medical School. It is currently in Phase 1 development.
At a glance
| Generic name | clofarabine, cytarabine, idarubicin |
|---|---|
| Sponsor | Hannover Medical School |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (PHASE2)
- Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) (PHASE3)
- Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) (PHASE2)
- Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (PHASE3)
- Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) (PHASE2)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clofarabine, cytarabine, idarubicin CI brief — competitive landscape report
- clofarabine, cytarabine, idarubicin updates RSS · CI watch RSS
- Hannover Medical School portfolio CI
Frequently asked questions about clofarabine, cytarabine, idarubicin
What is clofarabine, cytarabine, idarubicin?
clofarabine, cytarabine, idarubicin is a Small molecule drug developed by Hannover Medical School.
Who makes clofarabine, cytarabine, idarubicin?
clofarabine, cytarabine, idarubicin is developed by Hannover Medical School (see full Hannover Medical School pipeline at /company/hannover-medical-school).
What development phase is clofarabine, cytarabine, idarubicin in?
clofarabine, cytarabine, idarubicin is in Phase 1.